Changes of vitamin D levels and bone turnover markers after CPAP therapy: a randomized sham-controlled trial.
J Sleep Res. 2018 Aug;27(4):e12606. doi: 10.1111/jsr.12606
Theorell-Haglöw J1,2, Hoyos CM1, Phillips CL1, Yee BJ1, Herrmann M3, Brennan-Speranza TC4, Grunstein RR1, Liu PY5.
Interesting: It appears that 12 weeks (RCT) did not help, but that 24 weeks did
- Sleep Apnea 1.8 X more likely if poor Vitamin D Receptor – Dec 2018
- The worse the sleep apnea, the lower the vitamin D levels – meta-analysis Dec 2017
Sleep category starts with
- Sleep problems cured by vitamin D, etc. – workshops and patient workbooks – Gominak 2018
- Restless Legs Syndrome dramatically reduced by vitamin D, etc
- Iron deficiency is a cause of Vitamin D deficiency Depression
- On the job sleepiness 2.2X more likely if low vitamin D – Feb 2020
- Poor sleep 1.5 X more likely if less than 20 ng of Vitamin D – Feb 2019
- The Better Sleep Vitamin (Vitamin D) – nice 3 dollar book Feb 2015
- Seach VitaminDWiki for "SLEEP APNEA" 308 items as of Oct 2019
- Search VitaminDWiki for (sleep OR insomnia) Magnesium 307 items as of July 2020
The aim was to investigate whether continuous positive airway pressure treatment could modulate serum vitamin D (25-hydroxyvitamin D) and bone turnover markers (collagen-type 1 cross-linked C-telopeptide, osteocalcin and N-terminal propeptide of type 1 collagen) in secondary analysis from a randomized controlled trial. Sixty-five continuous positive airway pressure-naïve male patients with obstructive sleep apnea (age = 49 ± 12 years, apnea-hypopnea index = 39.9 ± 17.7 events h-1 , body mass index = 31.3 ± 5.2 kg m-2 ) were randomized to receive either real (n = 34) or sham (n = 31) continuous positive airway pressure for 12 weeks. At 12 weeks, all participants received real continuous positive airway pressure for an additional 12 weeks. After 12 weeks of continuous positive airway pressure (real versus sham), there were no between-group differences for any of the main outcomes [Δ25-hydroxyvitamin D: -0.80 ± 5.28 ng mL-1 (mean ± SE) versus 3.08 ± 3.66 ng mL-1 , P = 0.42; Δcollagen-type 1 cross-linked C-telopeptide: 0.011 ± 0.014 ng mL-1 versus -0.004 ± 0.009 ng mL-1 , P = 0.48; Δosteocalcin: 1.13 ± 1.12 ng mL-1 versus 0.46 ± 0.75 ng mL-1 , P = 0.80; ΔN-terminal propeptide of type 1 collagen: 2.07 ± 3.05 μg L-1 versus -1.05 ± 2.13 μg L-1 , P = 0.48]. There were no further differences in subgroup analyses (continuous positive airway pressure-compliant patients, patients with severe obstructive sleep apnea or sleepy patients). However, after 24 weeks irrespective of initial randomization, vitamin D increased in patients with severe obstructive sleep apnea (9.56 ± 5.51 ng mL-1 , P = 0.045) and in sleepy patients (14.0 ± 4.69 ng mL-1 , P = 0.007). Also, there was a significant increase in osteocalcin at 24 weeks (3.27 ± 1.06 ng mL-1 , P = 0.01) in compliant patients. We conclude that 12 weeks of continuous positive airway pressure did not modulate vitamin D or modulate any of the bone turnover markers compared with sham. However, it is plausible that continuous positive airway pressure may have late beneficial effects on vitamin D levels and bone turnover markers in selected groups of patients with obstructive sleep apnea.
Serum vitamin D levels in patients with obstructive sleep apnea syndrome and level changes after continuous positive airway pressure therapy
Sleep Breathing Physiology and Disorders 01 August 2020 https://doi.org/10.1007/s11325-020-02146-6
Dimitra I. Siachpazidou, Ourania S. Kotsiou, Vasileios Stavrou, Chaido Pastaka, Eudoxia Gogou, Maria Kechagia, Charalampos Varsamas, Nicholas-Tiberio Economou, Spyridon Zouridis, Eleni Patrikioy, George Seitanidis, Maria Pinaka, Alexandra Sistou, Chrissi Hatzoglou & Konstantinos I. Gourgoulianis
Patients with obstructive sleep apnea syndrome (OSAS) have been found to exhibit lower serum vitamin D levels, even when the control groups are matched for confounding conditions. However, contradictory studies are also present. This study aimed to compare serum 25-hydroxyvitamin D (25(OH)D) levels between adult patients with OSAS and non-apneic controls and to evaluate the changes in 25(OH)D levels after 3 and 12 months of continuous positive airway pressure (CPAP) therapy.
The study was comprised of 30 patients with OSAS and 30 controls. Serum 25(OH)D levels were determined at baseline and after 3 and 12 months of CPAP therapy in all patients with OSAS. For analysis, patients with OSAS were divided into subgroups by adherence, with adherence defined as CPAP usage for > 4 h per night on at least 70% of nights.
The 25(OH)D levels were not significantly different between OSAS and control groups at baseline. 25(OH)D levels did not change after 3 and 12 months of CPAP therapy. Patients who were CPAP-adherent showed less reduction in 25(OH)D levels compared with non-adherent ones (21.18 ± 9.3 vs. 12.13 ± 3.8 ng/mL, p = 0.022) after 1 year. The 25(OH)D levels were significantly correlated with higher daily CPAP usage at 3 and 12 months. Mean daily CPAP usage was a significant predictor of serum 25(OH)D levels at 12 months.
Patients with OSAS who demonstrated good CPAP adherence showed significantly higher 25(OH)D levels after 1 year compared with those not adequately using CPAP. Long-term good CPAP adherence and highly daily CPAP usage positively affected 25(OH)D levels in patients with OSAS.
There have actually been
|46 visitors, last modified 01 Aug, 2020,